U.S. Acute Respiratory Infection Treatment Market Size, Share, Growth, Trends, and Industry Analysis: By Infection Type (Viral (Adeno, COVID, HMPV, Influenza, PIV, RSV) and Bacterial (Bordetella Pertussis, Haemophilus Influenza, Mycoplasma Pneumoniae, Streptococcus Pneumoniae, Legionella Pneumophila, Others)), By Drug Class (Antibiotics, Antivirals, NSAIDS, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Country

U.S. Acute Respiratory Infection Treatment Market size was valued at US$ 1,363 million in 2023 and is projected to reach US$ 2,981 million by 2030, growing at a significant CAGR 1.4%. Influenza activity has been rising in some parts of the United States, leading to elevated hospitalizations due to which the number of Acute Respiratory Infectious patients the population reached 61,065 thousand in 2023 and there is a sharp increase in the patient population with ARIs from 2024 and is expected to reach a patient population of 77,109 thousand by 2030. Acute respiratory infections (ARIs) are a significant public health concern in the United States, encompassing a range of conditions from the common cold to more severe illnesses like pneumonia.

The market is driven by factors such as the high incidence of respiratory infections, growing awareness about early treatment, advancements in diagnostic technologies, and the development of novel therapeutic options. Additionally, Rise in cases of SARS and support from government and private organizations for R&D and production results in high demand in the market. However, challenges such as antibiotic resistance, the emergence of new pathogens, and the impact of seasonal variations on infection rates may affect market growth.

Key Developments

• In December 2023, AstraZeneca entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines, a protein virus-like particle (VLP) platform. The acquisition was based on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune therapies.
• In May 2023, GSK plc received US Food and Drug Administration (FDA) approval Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by RSV in 60 years of age and older population. This is the first RSV vaccine for older adults to be approved globally.